Breaking News

Europe Authorizes Anti-IL-6 Receptor Biologic to Treat Severe COVID-19 Patients

December 7, 2021 • 1:14 pm CST
(Precision Vaccinations)

Basel-based Roche announced that the European Commission (EC) had extended the marketing authorization for Actemra® / RoActemra® today to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Following the recent emergence of the new SARS-CoV-2 variant of concern, Omicron (B.1.1.529), the World Health Organization (WHO) has reported that interleukin 6 receptor blockers, such as Actemra/RoActemra, are expected to still be effective for managing patients with severe COVID-19.

"Actemra/RoActemra is the second Roche medicine to have received rapid European Commission approval in COVID-19 in recent weeks," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development, in a press statement.

"The totality of evidence shows that Actemra/RoActemra can benefit those suffering from severe COVID-19."

The decision from the EC today follows an accelerated assessment by the EMA's CHMP, which reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.

Outside of the European Union, Actemra/RoActemra has been provisionally approved in Australia, authorized for emergency use in the U.S. and Ghana, and recommended by the World Health Organization to treat COVID-19.

Roche is working closely with regulatory bodies and other partners worldwide on the next steps to bring this medicine to as many people as possible.

Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 110 countries worldwide. It was the first approved anti-IL-6 receptor biologic and is available in intravenous and subcutaneous formulations to treat adult patients with moderate-to-severe active rheumatoid arthritis.

In 2020, Roche entered into several new partnerships, including Regeneron (REGEN-CoV) and Gilead, to develop, manufacture, and distribute molecules that can potentially treat and prevent COVID-19.

The Roche Group, headquartered in Basel, Switzerland, was founded in 1896 and is active in over 100 countries and employed more than 100,000 people worldwide in 2020.

Medical Review by
Share